Tissue homeostasis relies on the activity of a small population of adult stem cells that have the capacity to generate short-lived differentiated cells while maintaining their identity through self-renewal^[@R1]^. Recently, in vivo clonogenic studies have revealed that within the mature T cell compartment, adult stem cells are confined to the CD62L^+^ memory T cell pool (which comprises stem cell--like memory (T~SCM~) and central memory T (T~CM~) cells)^[@R2],\ [@R3],\ [@R4]^. There has been growing interest in the identification of the molecular, epigenetic and metabolic factors orchestrating the formation and maintenance of stem cell--like T cells, since these cells are known to be critical for the long-term efficacy of T cell-based immunotherapy and vaccines^[@R5]^.

It has become increasingly clear that several transcriptional networks regulating stem cell behavior are also utilized by T cells to promote the development and maintenance of stem cell--like memory cells and to restrain terminal effector differentiation^[@R5],\ [@R6]^. For instance, Forkhead box protein O1 (Foxo1), T cell factor 1 (Tcf1), Signal transducer and activator of transcription 3 (STAT3) and the DNA-binding protein inhibitor Id3, which are essential for embryonic stem cell homeostasis and pluripotency^[@R7],\ [@R8],\ [@R9],\ [@R10]^, have been shown to regulate T cell stemness and the formation of memory T cells^[@R11],\ [@R12],\ [@R13],\ [@R14],\ [@R15],\ [@R16]^.

*MYB* --which encodes the transcription factor c-MYB-- is highly expressed in human stem cell--like memory CD8^+^ T cells compared to both naïve and effector memory cells^[@R17]^. In mouse models, c-Myb regulates thymocyte development^[@R18]^ and regulatory T cell effector differentiation^[@R19]^, but its function in CD8^+^ T cells is unknown. Given the critical role of c-Myb in the regulation of stem cells and progenitor cells in diverse tissues, including the bone marrow, colonic crypts and neurogenic regions of the brain^[@R20],\ [@R21]^, we hypothesized that it also plays a pivotal role in the regulation of stem cell--like behavior in T cells.

Herein, we determine that c-Myb is a critical regulator of CD8^+^ T cell stemness. c-Myb promoted pro-memory and survival programs via *Tcf7* (which encodes Tcf1) and *Bcl2* induction, and limited effector differentiation through *Zeb2* repression. We further show that while the c-Myb transactivation domain (TAD) is pivotal for restraining CD8^+^ T cell differentiation, the negative regulatory domain (NRD) mediated cell survival processes. Finally, we demonstrate that the activity of c-Myb can be therapeutically harnessed to enhance the formation of stem cell--like T~CM~ cells and promote curative antitumor immunity in a melanoma model of adoptive immunotherapy.

RESULTS {#S1}
=======

c-Myb promotes the formation of stem cell--like T~CM~ cells by restraining terminal differentiation. {#S2}
----------------------------------------------------------------------------------------------------

To evaluate the role of c-Myb in T cell differentiation we employed pmel-1 CD8^**+**^ T cells (which recognize the shared melanoma-melanocyte differentiation antigen gp100)^[@R22]^ carrying loxP-flanked *Myb* alleles. Because c-Myb plays critical roles during thymocyte development^[@R18]^, we bred a conditional knockout model based on a tamoxifen-regulated form of Cre (*Cre-ER*^*T2*^)^[@R23]^, pmel-1 *cre-ER*^*T2*^ *Myb*^fl/fl^, to acutely delete *Myb* in mature CD8^**+**^ T cells ([Fig. 1a](#F1){ref-type="fig"}). Naive pmel-1 *Myb*^Δ/Δ^ or pmel-1 *Myb*^+/+^ T cells isolated from littermates ([Fig. 1b](#F1){ref-type="fig"}) were adoptively transferred into wild-type mice infected with a recombinant strain of vaccinia virus encoding gp100 (gp100-VV) and antigen-specific CD8^+^ T cell expansion and persistence was monitored over time ([Fig. 1c](#F1){ref-type="fig"}). We found that in the absence of *Myb*, CD8^+^ T cells showed a minor defect in splenic accumulation during the acute phase of the immune response ([Fig. 1d,e](#F1){ref-type="fig"}). However, following the peak of expansion, c-Myb-deficient T cell numbers contracted more sharply than wild-type cells, resulting in fewer memory cells one month after transfer. A steep decline in c-Myb deficient CD8^+^ T cell frequency during the contraction phase was similarly observed in lymph nodes ([Supplementary Fig. 1a,b](#SD2){ref-type="supplementary-material"}) and lungs ([Supplementary Fig. 1c,d](#SD2){ref-type="supplementary-material"}), underscoring the importance of c-Myb in cell maintenance.

To determine whether the reduced accumulation of c-Myb-deficient CD8^+^ T cells was due to defects in proliferation, we measured 5-bromo-2'-deoxyuridine (BrdU) uptake in transferred cells responding to gp100-VV infection. Early on, the vast majority of antigen-specific cells were vigorously proliferating, independent of the presence of c-Myb ([Supplementary Fig. 2a,b](#SD2){ref-type="supplementary-material"}). Surprisingly, a significant fraction of c-Myb-deficient T cells continued to uptake BrdU, while most wild-type CD8^+^ T cells stopped actively dividing at the peak of expansion ([Supplementary Fig. 2a,b](#SD2){ref-type="supplementary-material"}). Thus, reduced accumulation of *Myb*^Δ/Δ^ T cells was not caused by defective proliferation. Therefore, we determined if the differences in cell numbers were linked to a survival disadvantage. Measuring apoptosis with Annexin V revealed that in the absence of *Myb*, CD8^+^ T cells underwent massive apoptosis in the initial phase of the immune response ([Supplementary Fig. 2c,d](#SD2){ref-type="supplementary-material"}). This tendency, though not statistically significant, was also observed at the peak of the response ([Supplementary Fig. 2c,d](#SD2){ref-type="supplementary-material"}). These data emphasize a pivotal role of c-Myb in mature T cell survival, consistent with known findings in thymocytes^[@R18],\ [@R24]^.

Increased turnover and apoptosis of pmel-1 *Myb*^Δ/Δ^ T cells might result from alteration of their differentiation program. We, therefore, evaluated the frequency of memory precursors and terminally differentiated effector (T~TE~) cells by measuring the expression of KLRG1 and CD62L on transferred pmel-1 T cells five days after gp100-VV infection. The deletion of *Myb* resulted in a 4-fold increase of splenic KLRG1^+^CD62L^−^ T~TE~ cells and a dramatic loss of KLRG1^−^CD62L^+^ memory precursors compared to controls ([Fig. 1f,g](#F1){ref-type="fig"}). Similarly, there was a marked accumulation of T~TE~ cells and depletion of CD62L^+^ cells in c-Myb-deficient T cells in lymph nodes and lungs ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). These findings were also observed when physiological numbers of antigen-specific T cells^[@R25]^ were transferred (data not shown). Although we did not measure major differences in perforin expression (data not shown), *Myb*-deficient T cells displayed higher amount of granzyme B ([Fig. 1h](#F1){ref-type="fig"}) and enhanced killing capacity in vitro ([Fig. 1i](#F1){ref-type="fig"}), further supporting the observation that c-Myb inhibits terminal effector differentiation. As T cells progressively differentiate into T~TE~ cells, they first lose the capacity to produce interleukin-2 (IL-2) and then tumor necrosis factor (TNF), before ultimately becoming monofunctional interferon (IFN)-γ producers^[@R26]^. *Myb*^Δ/Δ^ T cells exhibited poor polyfunctionality as evidenced by the reduced frequency of IL-2^+^TNF^+^ IFN-γ^+^ cells ([Fig. 1j,k](#F1){ref-type="fig"}). Notably, nearly half of cytokine producing *Myb*^Δ/Δ^ T cells were single IFN-γ producers, functionally consistent with our observation that CD8^+^ T cells were driven towards terminal differentiation in the absence of c-Myb. T cell differentiation is also intrinsically linked to changes in metabolism. For instance, effector T cells display reduced oxidative metabolism and mitochondrial spare respiratory capacity (SRC) compared to memory cells^[@R27]^. Accordingly, *Myb*^Δ/Δ^ T cells displayed a lower basal oxygen consumption rate and a striking reduction in SRC compared to wild-type cells ([Fig. 1l--n](#F1){ref-type="fig"}). Interestingly, these differences in cellular metabolism were in part independent of a skewed T~TE~ cell frequency as manifested by a small but significant reduction of mitochondrial fatty acid oxidation in *Myb*-deficient T cells after phenotypic normalization ([Supplementary Fig.4](#SD2){ref-type="supplementary-material"}). Taken together, phenotypic, functional and metabolic analyses concordantly demonstrate that c-Myb restrains CD8^+^ T cell terminal differentiation.

Consistent with a reduction of memory precursors generated in the acute phase of the immune response, we observed both decreased quantities of total memory cells ([Fig. 1d,e](#F1){ref-type="fig"}) and frequencies of stem cell--like T~CM~ cells in *Myb-*deficient T cells 30 days after transfer ([Fig. 1o,p](#F1){ref-type="fig"}). The hallmark function of memory cells is the ability to mount a robust response upon secondary infection. To determine whether *Myb*-deficient memory T cells were functionally competent, we transferred equal numbers of *Myb*^Δ/Δ^ or wild-type memory T cells into syngeneic hosts and measured their expansion 5 days after infection with a gp100 encoding adenovirus (gp100-Adv). Strikingly, we observed a dramatic impairment of *Myb*^Δ*/*Δ^ T cells to mount secondary immune responses ([Fig. 1q,r](#F1){ref-type="fig"}). Altogether, these results demonstrate that c-Myb is essential for the generation of long-lived and functional stem cell--like T~CM~ cells.

c-Myb is indispensable for CD8^+^ T cell stemness {#S3}
-------------------------------------------------

Persistence is a hallmark of stemness^[@R4]^. To determine the role of c-Myb in the persistence of CD8^+^ T cells we first evaluated the long-term maintenance of memory cells generated in the absence of *Myb* by measuring the frequency and number of adoptively transferred pmel-1 *Myb*^Δ*/*Δ^ or pmel-1 *Myb*^+*/*+^ T cells 90 days after infection with gp100-VV ([Fig. 2a](#F2){ref-type="fig"}). Notably, we found a striking reduction of total and stem cell--like T~CM~ cell numbers in the spleens of mice that received *Myb*-deficient cells compared to controls ([Fig. 2b,c](#F2){ref-type="fig"}). The reduction of *Myb*^Δ*/*Δ^ T cell numbers was not due to a skewed distribution because *Myb*^Δ*/*Δ^ T cells were similarly decreased in lungs and lymph nodes ([Supplementary Fig. 5a--d](#SD2){ref-type="supplementary-material"}). Compared to d30 ([Fig. 1d,e](#F1){ref-type="fig"}), we observed wider differences in cell frequencies and numbers indicating that memory cells undergo progressive attrition in the absence of c-Myb.

Secondly, we determined the ability of *Myb*-deficient T cells to generate secondary memory cells. We transferred equal numbers of memory cells generated 45 days after primary infection into secondary recipients and assessed the frequency and number of pmel-1 *Myb*^Δ*/*Δ^ or pmel-1 *Myb*^+*/*+^ T cells one month after infection with gp100-Adv ([Fig. 2d](#F2){ref-type="fig"}). *Myb*-deficient T cells exhibited a reduced capacity to form secondary memory cells in all organs evaluated ([Fig. 2e,f](#F2){ref-type="fig"} and [Supplementary Fig. 5e--h](#SD2){ref-type="supplementary-material"}). More importantly, the generation of stem cell--like T~CM~ cells was markedly impaired as evidenced by a 98.8% reduction in splenic CD62L^+^ T cell numbers ([Fig. 2g,h](#F2){ref-type="fig"}).

Finally, we tested the impact of *Myb*-deficiency on stem cell--like T~CM~ cell self-renewal. We labeled flow cytometric-sorted CD62L^+^ memory cells with carboxyfluorescein succinimidyl ester (CFSE) and transferred them into sub-lethally irradiated mice ([Fig. 2i](#F2){ref-type="fig"}). Four weeks later, we measured CFSE dilution and maintenance of a stem cell--like phenotype under homeostatic proliferation. Wild-type cells displayed robust self-renewal as shown by the retention of CD62L expression on CFSE-diluted cells ([Fig. 2j](#F2){ref-type="fig"}). *Myb*-deficient cells were unable to persist ([Fig. 2j](#F2){ref-type="fig"}). Of note, only half of the few surviving cells were able to maintain their stem cell--like phenotype ([Fig. 2j](#F2){ref-type="fig"}). Taken together, these experiments indicate that c-Myb is an essential regulator of CD8^+^ T cell stemness.

c-Myb enhances CD8^+^ T cell stemness by regulating *Tcf7, Bcl2* and *Zeb2* expression {#S4}
--------------------------------------------------------------------------------------

To understand mechanisms by which c-Myb regulates CD8^+^ T cell differentiation, we performed RNA-seq of pmel-1 *Myb*^+/+^ and pmel-1 *Myb*^Δ/Δ^ CD8^+^ T cells harvested 5 days after adoptive transfer into mice infected with gp100-VV. To minimize skewing in gene expression due to differences in T cell subset distribution among *Myb*^+/+^ and *Myb*^Δ/Δ^ T cells, we analyzed KLRG1^−^CD62L^−^ cells sorted with a purity \> 99% by flow cytometry ([Supplementary Fig. 6a](#SD2){ref-type="supplementary-material"}). Even after subset normalization, *Myb*^Δ/Δ^ T cells were enriched with genes known to be highly expressed in effector cells, whereas *Myb*^+/+^ T cells contained a higher proportion of transcripts associated with memory precursors ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 6b,c](#SD2){ref-type="supplementary-material"}, and [Supplementary Table 1](#SD3){ref-type="supplementary-material"}). To elucidate downstream effectors of c-Myb, we filtered the dataset by selecting genes reported to be directly regulated (activated or repressed) by c-Myb in promyelocytes^[@R28]^. *Bcl2*, a well-established target of c-Myb^[@R29],\ [@R30]^, was downregulated in *Myb*^Δ/Δ^ T cells ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Table 1](#SD3){ref-type="supplementary-material"}), in keeping with the survival defect observed in pmel-1 *Myb*^Δ/Δ^ T cells ([Supplementary Fig 2c,d](#SD2){ref-type="supplementary-material"}). Pathway analysis further revealed induction of transcriptional networks promoting cell death among *Myb*^Δ/Δ^ T cells ([Supplementary Table 2](#SD3){ref-type="supplementary-material"}). Two crucial transcription factors regulating CD8^+^ T cell differentiation, *Tcf7* and *Zeb2*^[@R13],\ [@R14],\ [@R31],\ [@R32]^ were differentially expressed in *Myb*^Δ/Δ^ and *Myb*^+/+^ cells ([Fig. 3a](#F3){ref-type="fig"} and [Supplementary Table 1](#SD3){ref-type="supplementary-material"}). *Tcf7*, which enhances the formation and maintenance of memory T cells, was downregulated in *Myb*^Δ/Δ^ T cells. Conversely, Zeb*2*, a driver of CD8^+^ T cell terminal differentiation^[@R31],\ [@R32]^, was upregulated in the absence of *Myb* ([Fig. 3a](#F3){ref-type="fig"}). Gene Set Enrichment Analysis (GSEA) corroborated these findings by revealing that *Myb*^Δ/Δ^ T cells were enriched with genes upregulated in CD8^+^ T cells lacking WNT-reporter activity^[@R33]^ ([Fig. 3b](#F3){ref-type="fig"}, left panel) and genes upregulated in *Zeb2*-sufficient CD8^+^ T cells^[@R32]^ ([Fig. 3b](#F3){ref-type="fig"}, right panel).

To further elucidate the relationship of *Myb* expression with that of *Bcl2*, *Tcf7* and *Zeb2* during CD8^+^ T cell differentiation, we quantified the transcripts of these genes in naïve, CD62L^+^ and CD62L^*−*^ pmel-1 T cells generated in response to gp100-VV. As *Myb* expression declined with differentiation from naive T cells into CD62L^−^ cells, *Bcl2* and *Tcf7* transcripts decreased ([Fig. 3c,d](#F3){ref-type="fig"}), whereas *Zeb2* expression was inversely related to *Myb* expression([Fig. 3e](#F3){ref-type="fig"}). We next sought to evaluate how the genetic manipulation of *Myb* would affect *Bcl2*, *Tcf7* and *Zeb2* expression. To this end, we adoptively transferred into gp100-VV infected mice pmel-1 *Myb*^+/+^, pmel-1 *Myb*^Δ/Δ^ and pmel-1 T cells transduced with *Myb*-Thy1.1 or Thy1.1 alone. Five days later, we analyzed *Bcl2*, *Tcf7* and *Zeb2* expression in transferred T cells. Reinforcing our RNA-seq results, *Myb* deletion resulted in significant reduction of *Bcl2* and *Tcf7* ([Fig. 3f,g](#F3){ref-type="fig"}), while dramatically increasing *Zeb2* expression ([Fig. 3h](#F3){ref-type="fig"}). By contrast, *Myb* overexpression enhanced both *Bcl2* and *Tcf7* ([Fig. 3f,g](#F3){ref-type="fig"}) and suppressed *Zeb2* expression ([Fig. 3h](#F3){ref-type="fig"}). Similar findings were obtained by measuring Bcl2 and Tcf1 proteins ([Fig. 3i,j](#F3){ref-type="fig"}). The lack of working mouse Zeb2-specific antibodies prevented assessment of the impact of c-Myb on Zeb2 protein expression. Transcriptional regulation of *Tcf7* by c-Myb was confirmed by a *Tcf7GFP* reporter assay in CD8^+^ T cells after overexpression of *Myb* (data not shown). *Bcl2* is regulated by c-Myb^[@R30]^. Whether c-Myb directly binds and regulates *Tcf7* and *Zeb2* expression in CD8^+^ T cells merited further analysis. We performed chromatin immunoprecipitation (ChIP) followed by quantitative PCR in pmel-1 *Myb*^+/+^ and *Myb*^Δ/Δ^ CD8^+^ T cells and found a specific enrichment of *Tcf7* enhancer and *Zeb2* promoter regions with c-Myb immunoprecipitation in wild-type cells but not in *Myb*^Δ/Δ^ T cells ([Fig. 3k](#F3){ref-type="fig"}). Taken together, these findings place c-Myb as a transcriptional activator of *Bcl2* and *Tcf7*, and as a transcriptional repressor of *Zeb2* in CD8^+^ T cells.

We next sought to determine if the tendency for *Myb*^Δ/Δ^ T cells to undergo terminal differentiation depends on insufficient levels of *Tcf7* and unrestrained expression of *Zeb2*. To this end, we adoptively transferred pmel-1 *Myb*^Δ/Δ^ T cells and pmel-1 *Myb*^Δ/Δ^ *Zeb2*^+/Δ^ T cells transduced with either *Tcf7-GFP* or *GFP* alone in gp100-VV infected mice and evaluated the formation of KLRG1^+^CD62L^*−*^ T~TE~ cells in comparison with pmel-1 *Myb*^fl/fl^ transduced with *GFP* control. Testing complete *Zeb2* deficiency on pmel-1 *Myb*^Δ/Δ^ T cells was not possible. The *Zeb2* loci is located on chromosome 2, just 12 centimorgans from the insertion site of the pmel-1 *Tcra* and *Tcrb* transgenes^[@R22]^, therefore there is a slim probability of obtaining a *Zeb2*^fl/fl^ with pmel-1 background. Consistent with our results using naïve CD8^+^ T cells ([Fig. 1f,g](#F1){ref-type="fig"}), *in vitro* activated pmel-1 cells engineered to express GFP alone generated higher frequencies of T~TE~ cells in the absence of *Myb* ([Fig. 3l,m](#F3){ref-type="fig"} top). Individually, overexpression of *Tcf7* or *Zeb2* haploinsufficiency significantly reduced the frequency of T~TE~ cells in pmel-1 *Myb*^Δ/Δ^ *GFP* T cells, though *Zeb2* depletion had a more pronounced effect ([Fig. 3l,m](#F3){ref-type="fig"} top). Remarkably, the combination of both genetic approaches completely rescued the skewed differentiation pattern of pmel-1 *Myb*^Δ/Δ^ *GFP* T cells ([Fig. 3l,m](#F3){ref-type="fig"} top). Despite correcting the differentiation program, these genetic maneuvers did not rescue the survival defects of pmel-1 *Myb*^Δ/Δ^ T cells, implicating *Bcl2* and other downstream factors behind the pro-survival function of c-Myb ([Fig. 3l,m](#F3){ref-type="fig"} bottom). Thus, c-Myb promotes CD8^+^ T cell stemness both by inducing pro-memory and survival programs via *Tcf7* and *Bcl2*, and by restraining effector differentiation through suppression of *Zeb2.*

Distinct functions of c-Myb domains in the regulation of CD8^+^ T cell differentiation and survival {#S5}
---------------------------------------------------------------------------------------------------

To further characterize the molecular mechanisms by which c-Myb regulates CD8^**+**^ T cell differentiation and survival, we generated a complement of *Myb* mutants and tested their ability to rescue the phenotype of pmel-1 *Myb*^Δ/Δ^ T cells. We compared full length *Myb* activity to that of three different *Myb* mutants^[@R34]^: a truncated *Myb* lacking the NRD (*Myb 1--330*); a *Myb* mutant with a non-functional TAD (glycine, proline insertion after the 304-amino acid residue, *Myb 304GP*); and a truncated *Myb* comprising the DNA binding domain only (*pBind*) ([Fig. 4a](#F4){ref-type="fig"}). These *Myb* mutants were cloned into a MSGV-Thy1.1 retroviral vector to allow sorting and tracking of transduced pmel-1 cells after adoptive transfer into wild-type mice infected with gp100-VV ([Fig. 4a](#F4){ref-type="fig"}). With the exception of the *pBind* construct, which resulted in higher levels of *Myb* transcription, all other vectors induced comparable levels of *Myb* transcripts (data not shown). As we previously observed, pmel-1 *Myb*^Δ*/*Δ^ Thy1.1 CD8^+^ T cells generated higher frequencies of T~TE~ cells at the peak of the immune response compared to pmel-1 *Myb*^+*/*+^ Thy1.1 T cells ([Fig. 4b,c](#F4){ref-type="fig"}). As expected, full length *Myb* significantly reduced the percentage of T~TE~ cells ([Fig. 4b,c](#F4){ref-type="fig"}). Strikingly, *Myb* (*1--330*) not only abrogated the generation of T~TE~ cells but also dramatically increased the frequency of CD62L^+^ memory precursors ([Fig. 4b,c](#F4){ref-type="fig"}), confirming NRD self-regulation of *Myb* in CD8^+^ T cells. Conversely, *Myb pBind* and *304GP* failed to rescue the phenotype of pmel-1 *Myb*^Δ/Δ^ T cells ([Fig. 4b,c](#F4){ref-type="fig"}) demonstrating the indispensable function of the c-Myb TAD in restraining CD8^+^ T cell terminal differentiation. Notably, these functional differences among *Myb* mutants correlated with their abilities to induce *Tcf7* expression and repress *Zeb2* transcription. Full length *Myb* and *Myb* (*1--330*), which both inhibited CD8^+^ T cell terminal differentiation, promoted *Tcf7* expression and decreased *Zeb2* transcripts compared to pmel-1 *Myb*^Δ*/*Δ^ Thy1.1 CD8^+^ T cells ([Fig. 4d,e](#F4){ref-type="fig"}). On the other hand, *Myb pBind*, which did not rescue the phenotype of pmel-1 *Myb*^Δ/Δ^ T cells, did not lower *Zeb2* expression and failed to induce *Tcf7* ([Fig. 4d,e](#F4){ref-type="fig"}). Interestingly, *Myb 304GP*, which was inefficient in inhibiting CD8^+^ T cell differentiation, did retain high levels of *Zeb2* and induce *Tcf7*, albeit to a lesser extent than full length *Myb* ([Fig. 4d,e](#F4){ref-type="fig"}). This emphasizes the prominent role of *Zeb2* over *Tcf7* in the regulation of T~TE~ cells. Thus, the c-Myb TAD restrains CD8^+^ T cell differentiation by promoting *Tcf7* expression but mostly by suppressing *Zeb2* transcription. Despite being unable to correct CD8^+^ T cell differentiation, *Myb 304GP* fully rescued the frequency and total number of pmel-1 *Myb*^Δ/Δ^ CD8^+^ T cells ([Fig. 4f,g](#F4){ref-type="fig"}). Evidently, the pro-survival effects of c-Myb are independent of its TAD activity and its regulation of *Tcf7* and *Zeb2* ([Fig. 3l,m](#F3){ref-type="fig"}, bottom). Further substantiating this conclusion, is the finding that *Myb* (*1--330*), which markedly inhibited CD8^+^ T cell differentiation, induced *Tcf7* and suppressed *Zeb2* expression, but did not increase pmel-1 T cell frequency and total number to the levels produced in *Myb*^+*/*+^ T cells ([Fig. 4f,g](#F4){ref-type="fig"}). Combined with the results from *Myb pBind* complementation ([Fig. 4f,g](#F4){ref-type="fig"}), the pro-survival activity of c-Myb is primarily linked to the integrity of its C-terminal domain. In summary, the c-Myb TAD is critical for regulating CD8^+^ T cell differentiation, but it is the NRD that is essential for maintaining cell survival.

Enforced *Myb* expression enhances CD8^+^ T cell stemness and polyfunctionality {#S6}
-------------------------------------------------------------------------------

Having demonstrated the pivotal role of c-Myb in the regulation of CD8^+^ T cell stemness, we next sought to determine if the generation of stem cell--like T~CM~ cells could be enhanced by enforcing *Myb* expression. We transduced pmel-1 Ly5.1^+^ CD8^+^ T cells with *Myb*-Thy1.1 and pmel-1 Ly5.2^+^ CD8^+^ T cells with Thy1.1 alone, mixed them at 1:1 ratio, and co-transferred into wild-type mice infected with gp100-VV ([Fig. 5a](#F5){ref-type="fig"}). Overexpression of c-Myb enhanced the expansion of splenic antigen-specific pmel-1 T cells, which accumulated at 4-fold the rate of controls at the peak of the immune response ([Fig 5b,c](#F5){ref-type="fig"}). Likewise, we observed an increased expansion of *Myb*-overexpressing pmel-1 T cells in lungs and lymph nodes, though the accumulation was more pronounced in the latter ([Supplementary Fig. 7a--d](#SD2){ref-type="supplementary-material"}). Enforcing *Myb* expression did not increase the numbers of pmel-1 T cells in the spleen and lungs thirty days after transfer ([Fig 5b,c](#F5){ref-type="fig"} and [Supplementary Fig. 7a,b](#SD2){ref-type="supplementary-material"}), indicating that c-Myb overexpression alone is insufficient to cause unrestrained T cell expansion or transformation^[@R20]^. We observed, however, a dramatic increase of pmel-1 T cells (\~50-fold) in the lymph nodes ([Supplementary Fig. 7c,d](#SD2){ref-type="supplementary-material"}), which prompted us to investigate whether the increased accumulation of *Myb*-overexpressing T cells in the lymph nodes was due to the preferential formation of stem cell--like T~CM~ cells, which preferentially home to lymphoid tissues. Consistent with our findings using c-Myb-deficient T cells, we found that overexpression of c-Myb promoted the generation of stem cell--like T~CM~ cells while restraining terminal effector differentiation ([Fig. 5d,e](#F5){ref-type="fig"} and [Supplementary Fig. 7e,f](#SD2){ref-type="supplementary-material"}). These results were further strengthened by functional studies, which revealed that *Myb*-overexpressing cells displayed enhanced polyfunctionality and a sustained capacity to produce IL-2 ([Fig. 5f--h](#F5){ref-type="fig"}). Taken together these results demonstrate that increasing *Myb* levels in CD8^+^ T cells is an effective strategy to generate polyfunctional stem cell--like T~CM~ cells.

Enforced expression of *Myb* enhances CD8^+^ T cell recall responses and antitumor immunity {#S7}
-------------------------------------------------------------------------------------------

The hallmark of memory cells is their capacity to rapidly proliferate and differentiate into a massive number of effectors upon secondary infection. To determine if the enhanced generation of stem cell-like T~CM~ cells resulting from c-Myb overexpression would promote stronger recall responses, we re-challenged mice that were initially infected with gp100-VV with gp100-adV ([Fig. 6a](#F6){ref-type="fig"}). Strikingly, the accumulation of splenic *Myb*-overexpressing T cells at the peak of the secondary immune response was 10-fold higher in frequency and number as compared to controls ([Figure 6b,c](#F6){ref-type="fig"}). Repeated antigen-stimulations are known to drive CD8^+^ T cells towards terminal differentiation^[@R35],\ [@R36]^. To determine whether terminal differentiation could be restrained by overexpressing c-Myb, we measured T~TE~ cells after secondary infection with gp100-adV. Remarkably, c-Myb overexpression not only dramatically reduced the frequencies of T~TE~ cells in both peripheral and lymphoid tissues ([Fig. 6d--i](#F6){ref-type="fig"}), but also maintained a higher fraction of stem cell--like T~CM~ cells. Moreover, intracellular cytokine staining analyses showed a marked reduction of terminally differentiated, monofunctional IFN-γ producers in the *Myb*-overexpression group ([Fig. 6j--l](#F6){ref-type="fig"}).

It is well-established that the dose of adoptively transferred tumor-specific CD8^+^ T cells correlates with the magnitude of tumor regression^[@R37]^. Generating large numbers of tumor-reactive T cells in vitro, however, can be counterproductive because as cells expand they progressively differentiate into T~TE~ cells with limited therapeutic fitness^[@R35]^. We sought to determine whether overexpression of c-Myb would not only generate larger cell numbers through repetitive antigenic stimulations but also preserve a larger number of stem cell--like T~CM~ cells. As we previously showed, antigen re-stimulation induced the formation of CD62L^*−*^ effector cells ([Fig. 7a,b](#F7){ref-type="fig"}). By contrast, the vast majority of pmel-1 T cells overexpressing c-Myb retained high CD62L expression throughout multiple stimulations ([Fig. 7a,b](#F7){ref-type="fig"}). Notably, restimulated T cells preserved their mitochondrial mass only when c-Myb was constitutively overexpressed ([Fig. 7c,d](#F7){ref-type="fig"}). Even after a multi-log expansion *Myb*-overexpressing T cells exhibited significant SRC and fatty acid metabolism ([Fig. 7 e--g](#F7){ref-type="fig"}), highlighting the importance of c-Myb in the maintenance of metabolic fitness. To evaluate their therapeutic efficacy, we adoptively transferred multiply stimulated, *Myb*-overexpressing pmel-1 T cells into mice bearing subcutaneous B16-hgp100 melanomas in conjunction with administration of IL-2. *Myb*-overexpressing T cells triggered curative responses in all mice, whereas controls cells failed to cure 4/5 animals ([Fig. 7h](#F7){ref-type="fig"}). Conversely, the antitumor efficacy of pmel-1 T cells was severely impaired in the absence of c-Myb (data not shown). To determine if the transfer of stem cell--like T~CM~ cells in the *Myb*-overexpression group conferred long-lasting antitumor memory responses we re-challenged the surviving animals with tumors around 200 days after the primary T cell transfer. Remarkably, tumors did not grow in any of the re-challenged animals ([Fig. 7h](#F7){ref-type="fig"}), indicating that overexpression of c-Myb enhances the establishment of long-lived immunological memory. Consistent with this observation, we found increased numbers of memory T cells in the surviving mice that received *Myb*-overexpressing T cells 470 days earlier ([Supplementary Fig. 8a,b](#SD2){ref-type="supplementary-material"}). Although all memory T cells displayed a stem cell--like T~CM~ phenotype ([Supplementary Fig.8c](#SD2){ref-type="supplementary-material"}), a larger fraction of *Myb*-overexpressing T cells was capable of producing IL-2 compared to controls ([Supplementary Fig.8d](#SD2){ref-type="supplementary-material"}). Taken together, these findings highlight the therapeutic potential of maneuvers aimed at increasing c-Myb activity in CD8^+^ T cells.

DISCUSSION {#S8}
==========

The molecular programs regulating the formation and maintenance of stem cell--like T~CM~ cells remains unresolved. In this current study, we identified c-Myb as a master regulator of CD8^+^ T cell stemness. In the absence of c-Myb, antigen-stimulated CD8^+^ T cells are driven toward terminal effector differentiation and are prone to apoptosis resulting in both quantitative and qualitative impairment of memory responses. These conclusions are further supported by the observation that CD8^+^ T cells deficient in the microRNA miR-150, a known inhibitor of c-Myb, have enhanced propensity to form long-lived memory T cells^[@R38]^. Our findings run in parallel to those in stem cells and progenitor cells where c-Myb is seen to restrain differentiation^[@R20],\ [@R21]^, illuminating a conserved molecular program regulating self-renewal and differentiation^[@R5]^.

Mechanistically, we demonstrated that c-Myb enhances CD8^+^ T cell survival and memory development by promoting the expression of the anti-apoptotic molecule *Bcl2* and by inducing *Tcf7*, a transcription factor essential to the formation and maintenance of stem cell--like T~CM~ cells ^[@R13],\ [@R14]^. Recently, Tcf1 expression has also been associated with the maintenance of CXCR5^+^Tim3^−^ stem cell--like T cells in chronic infection and cancer^[@R39],\ [@R40],\ [@R41],\ [@R42]^. Future work will determine whether c-Myb plays an important role in maintaining this cell population. We further demonstrated that c-Myb also actively repressed pro-differentiating programs by inhibiting the transcription of *Zeb2*, which we have recently identified as a major driver of terminal effector differentiation^[@R31]^. This result further emphasizes the understudied repressive function of c-Myb, often considered a transcriptional activator. The repressive activity of c-Myb has been linked to its competitive binding with positive transcription regulators to target gene promoters^[@R43]^ and to the recruitment of cell type-specific repressors^[@R44],\ [@R45]^. While we haven't formally addressed the latter mechanism, complementation studies with the *pBind* mutant unequivocally exclude a mechanism of competition with positive transcription regulators as the c-Myb DNA-binding domain failed to suppress *Zeb2* transcription and restore physiologic numbers of memory precursors on its own. Recently, it has been proposed that c-Myb-mediated repression might paradoxically involve its interaction with the coactivator p300 possibly through the induction of repressive non-coding RNAs^[@R28]^. Consistent with this view, we found that *Myb 304GP* which has been shown to have an impaired ability to recruit p300^[@R34]^ was unable to repress *Zeb2* and inhibit terminal effector differentiation.

Our complementation studies also indicate that the C-terminal NRD domain of c-Myb has an important function in regulating CD8^+^ T cell survival. The mechanistic basis of this finding remains to be elucidated. Myb NRD contains an EVES motif which has been shown to bind p100^[@R46]^. Although p100 overexpression inhibited the transcriptional activity of c-Myb in in vitro cultured fibroblasts^[@R46]^, this molecule has been demonstrated to function as a coactivator in other settings^[@R47]^ possibly implicating its involvement in the pro-survival programs triggered by c-Myb.

Finally, our study has profound therapeutic implications for T cell-based immunotherapy. Uncoupling T cell differentiation from T cell expansion has been sought after as the Holy Grail of adoptive immunotherapy as the therapeutic efficacy highly depends on both the cell dose and differentiation status of infused T cells^[@R37],\ [@R48]^. Thus far strategies that have been shown to effectively promote stem cell--like memory T cells have the downside effect of impairing cell expansion^[@R4],\ [@R17],\ [@R49],\ [@R50]^. Overexpression of c-Myb not only preserved CD8^+^ T cell stemness by inhibiting differentiation, but also allowed a better cell yield, resulting in curative antitumor responses and the establishment of long-term immunologic memory. The *Myb* platform may ultimately pave new avenues for the generation of cell-based immunotherapy based on the adoptive transfer of stem cell--like T~CM~ cells.

ONLINE METHODS {#S9}
==============

Mice {#S10}
----

C57BL/6NCr and B6-Ly5.1/Cr were from Charles River Frederick Research Model Facility; pmel-1 (B6. Cg-*Thy1*^a^/Cy Tg(TcraTcrb)8Rest/J) mice were from the Jackson Laboratory; Cre-ER^T2^ (B6-*Gt(ROSA)26Sor*^tm9(cre/Esr1)Arte^) mice were from Taconic. *Myb*^fl/fl^ mice^[@R18]^ were obtained from Timothy Bender, University of Virginia, Charlottesville, VA and were back-crossed with C57BL/6NCr mice for \>30 generations, USA; *Zeb2*^fl/fl^ mice were kindly obtained from Susan Kaech, Yale University, New Heaven, CT, USA. Pmel-1 mice were crossed with *Myb*^fl/fl^ mice for the generation of pmel-1 *Myb*^fl/fl^ mice and were further crossed with *Cre-ER*^*T2*^ mice for the generation of pmel-1 *Cre-ER*^*T2*^ *Myb*^fl/fl^ mice. pmel-1 Cre-ER^T2^ *Myb*^fl/fl^ mice were further crossed with *Zeb2*^fl/fl^ mice to obtain pmel-1 *Cre-ER*^*T2*^ *Myb*^fl/fl^ *Zeb2*^wt/fl^ mice. Spleens from *Tcf7*^GFP*/*+^ mice^[@R51]^ were obtained from Avinash Bhandoola, National Cancer Institute and Hai-Hui Xue, Iowa University. All mouse experiments were done with the approval of the National Cancer Institute Animal Care and Use Committee.

Cell lines {#S11}
----------

Platinum-E cells were obtained from Cell Biolabs following authentication and validation as being mycoplasma free. B16 melanoma expressing human gp100 (B16-hgp100)^[@R52]^ were provided by Ken-ichi Hanada, National Cancer Institute, Bethesda, MD and validated as being mycoplasma free via a PCR-based assay.

Antibodies, flow cytometry and cell sorting {#S12}
-------------------------------------------

Anti-BrdU (3D4), anti-Ly5.2 (104), anti-Thy1.1 (OX-7), anti-CD62L (MEL-14), anti-IFNγ (XMG1.2), anti-TNF (MP6-XT2) were from BD Biosciences; anti-CD8α (53--6.7), anti-KLRG-1 (2F1), anti-IL-2 (JE56--5H4), anti-CD44 (IM7), Bcl-2 (633504), anti-mouse Perforin Antibody (S16009A), anti-human/mouse granzyme B Antibody (GB11) were from Biolegend; anti-TCF1 (C63D9) was from Cell Signaling Technology. For intracellular staining of Tcf1, Bcl-2, granzyme B and perforin, cells were fixed and permeabilized (eBioscience, 00--5524). Leukocyte Activation Cocktail containing phorbol myristate acetate (PMA) and ionomycin (BD Biosciences) was used to stimulate T cells for intracellular cytokine staining. A Fixation/Permeabilization Solution Kit (BD Biosciences) was used to fix and permeabilize the cells. Annexin V staining was performed with Annexin V Apoptosis Detection Kit (eBiosciences). BrdU staining was performed with BrdU Staining Kit (eBiosciences) following the protocol provided by the manufacturer. LSR II or BDFortessa (BD Biosciences) were used for flow cytometry acquisition. Samples were analyzed with FlowJo software (TreeStar). Naive CD8^+^ T cells were enriched using Naïve CD8^+^ T cell isolation kit from Stem Cell Technology. A FACSAria (BD Biosciences) was employed for all other T cell enrichments.

Real-time RT-PCR {#S13}
----------------

RNA was isolated with an RNeasy Mini Kit (Qiagen). Reverse transcription PCR was performed to obtain cDNA (Applied Biosystems). Primers from Applied Biosystems and a Prism 7900HT (Applied Biosystems) were used for real-time PCR using Fast Start Universal SYBER GREEN Master (Roche). Results are presented relative to *Actb* or *Rpl13* expression.

List of primers used:

*Rpl13*F: CGAGGCATGCTGCCCCACAA

*Rpl13*R: AGCAGGGACCACCATCCGCT

*Bcl2*F: GTCGCTACCGTCGTGACTTC

*Bcl2*R: CAGACATGCACCTACCCAGC

*Zeb2*F: CCACGCAGTGAGCATCGAA

*Zeb2*R: CAGGTGGCAGGTCATTTTCTT

*Myb*F: AGACCCCGACACAGCATCTA

*Myb*R: CAGCAGCCCATCGTAGTCAT

*Tcf7*F: AGCTTTCTCCACTCTACGAACA

*Tcf7*R: AATCCAGAGAGATCGGGGGTC

*Eomes*F: GCGCATGTTTCCTTTCTTGAG

*Eomes*R: GGTCGGCCAGAACCACTTC

*Tbx21*F: AGCAAGGACGGCGAATGTT

*Tbx21*R: GGGTGGACATATAAGCGGTTC

*Prdm1*F: TTCTCTTGGAAAAACGTGTGGG

*Prdm1*R: GGAGCCGGAGCTAGACTTG

*Bach2*F: TCAATGACCAACGGAAGAAGG

*Bach2*R: GTGCTTGCCAGAAGTATTCACT

Immunoblot analysis {#S14}
-------------------

Proteins were separated by 4--12% SDS-PAGE, followed by standard immunoblot analysis with anti-Myb (Millipore, clone 1--1), anti-GAPDH (6C5; Santa Cruz Biotechnology), horseradish peroxidase--conjugated goat anti--mouse IgG (sc-2031; Santa Cruz Biotechnology) and horseradish peroxidase--conjugated goat anti--rabbit IgG (sc-2030; Santa Cruz Biotechnology).

Chromatin Immunoprecipitation {#S15}
-----------------------------

5 day *in vitro* cultured cells were crosslinked to chromatin by adding 1% formaldehyde to each culture dish at room temperature for 10 minutes and stopped by addition of 125 mM glycine followed by incubation at room temperature for 5 minutes. Cells were harvested, pelleted and washed with cold PBS. Cells were resuspended at 10^7^ cells/ml in cold cytoplasmic lysis buffer (20 mM Tris-HCl pH 8, 85 mM KCl, 0.5% NP-40, 1 mM PMSF and EDTA-free protease inhibitor mixture (Roche)) and incubated on ice for 10 minutes. Nuclei were centrifuged, resuspended at 10^7^ cells/ml in cold sonication buffer (10mM Tris-HCl pH 8, 0.1 mM EDTA, 1% NP-40, 0.01% SDS, 1 mM PMSF and EDTA-free protease inhibitor mixture) and sonicated using a Branson 450 sonifier to generate chromatin fragment. Debris was cleared by centrifugation and chromatin was supplemented with 5% glycerol and 127 mM NaCl. Chromatin aliquots of 500 μl were pre-cleared using protein A agarose slurry (Millipore, Bedford, MA) for 1 hour and immunoprecipitated over night with anti-Myb (A304--138A; Bethyl) or mouse IgG2a,κ isotype control (BD Biosciences, San Jose, CA) with rotation at 4^o^C. Immune complexes were collected with protein A agarose slurry for 1 hour with rotation at 4^o^C. Beads were washed for 5 minutes with rotation at 4^o^C with low salt buffer (10 mM Tris-HCl pH8, 2 mM EDTA, 0.1% SDS, 1% NP40, 150 mM NaCl), high salt buffer (10 mM Tris-HCl pH8, 2 mM EDTA, 0.1% SDS, 1% NP40, 500 mM NaCl), LiCl buffer (10 mM Tris-HCl pH8, 1mM EDTA, 1% Deoxycholate, 1% NP40, 250 mM LiCl) and twice in TE. All wash buffers were supplemented with protease inhibitors and PMSF. Bound complexes were eluted off the beads in 500 μl elution (0.1 M, 1% SDS) buffer with rotation at room temperature for 30 minutes. Formaldehyde crosslinking was reversed in the presence of 200 mM NaCl at 65^o^C overnight. DNA was phenol/chloroform extracted following RNAse A and proteinase K treatment.

ChIP PCR primers {#S16}
----------------

*Tcf7*F 5′- ATAACTGGTGCCATGACCGG-3′

*Tcf7R* 5′- CAGGGCTGGACAACACAAAG −3′

*Zeb2* primers were from Qiagen (GPM1048638(+)04A).

Retroviral vector construction and virus production {#S17}
---------------------------------------------------

*Myb* isoform 2 or its mutants' cDNA was cloned together into the MSGV-1-Thy1.1 vector as previously described^[@R16]^. Platinum-E cell lines were used for gamma-retroviral production by transfection with DNA plasmids through the use of Lipofectamine 2000 (Invitrogen) and collection of virus 40 h after transfection. pMIG empty vector and *Tcf7*- pMIG were obtained from Avanish Bhandoola, National Cancer Institute, Bethesda, MD, USA.

*In vitro* activation and transduction of CD8^+^ T cells {#S18}
--------------------------------------------------------

Naïve CD8^**+**^ T cells were activated on plates coated with anti-CD3ε (2 μg/ml; 145--2C11; BD Biosciences) and soluble anti-CD28 (1 μg/ml; 37.51; BD Biosciences) in culture medium containing recombinant human IL-2 (10 ng/ml; Prometheus Laboratories Inc). Virus was 'spin-inoculated' at 2,000*g* for 2 h at 32 °C onto plates coated with retronectin (Takara). CD8^+^ T cells activated for 24 h were spun onto plates after aspiration of viral supernatants. Transduction efficiency was then evaluated 48h later.

Tamoxifen treatment, adoptive cell transfer, infection, and tumor challenge {#S19}
---------------------------------------------------------------------------

Cre-ERT2-mediated deletion of floxed alleles was induced by intraperitoneal injection of 2 mg tamoxifen (Sigma-Aldrich) dissolved in corn oil (Sigma-Aldrich) for 4 consecutive days. Pmel-1 CD8^+^ T cells (600--3 X 10^5^ cells) were adoptively transferred into 6--10-week old C57BL/6 followed by infection with 2 X 10^7^ PFU recombinant vaccinia virus expressing human gp100 (gp100-VV). Recall response experiments were performed 30--45 days after primary infection with gp100-VV by either re-challenging mice with 10^8^ PFU recombinant adenovirus type 2 expressing human gp100 or by performing secondary adoptive transfer of normalized memory cell numbers. For homeostatic proliferation of memory CD8^+^ T cells, recipient mice were sub-lethally irradiated (5Gy) prior to cell transfer. For tumor experiments 6--10-week old C57BL/6 mice were injected subcutaneously with 2 X 10^5^ B16-hgp100. Mice were treated 10 days later with intravenous injection of 5 X 10^6^ pmel-1 CD8^**+**^ T cells. Mice were vaccinated intravenously with 2 X 10^7^ pfu gp100-VV and recombinant human IL-2 (2.4e5 IU/dose) was administered twice a day for a total of 6 doses. For long-term memory and secondary transfer experiments we employed recipient mice carrying the *Myb*^fl^ allele to avoid possible rejection. In these experiments, we used pmel CD8^+^ T cells from tamoxifen-treated littermates carrying the *Myb*^fl^ allele but not cre*ER*^*T2*^ as WT controls.

Quantification of adoptively transferred cells {#S20}
----------------------------------------------

Spleens were processed and cells were counted by trypan blue exclusion of dead cells. The frequency of transferred T cells was determined by measurement of the expression of CD8 and Thy1.1 or GFP or Thy1.1/Ly5.1 or Ly5.2 by flow cytometry. The absolute number of pmel-1 cells was calculated by multiplying the total cell count by the percentage of CD8^**+**^GFP^**+**^, CD8^**+**^Thy1.1^**+**^ or CD8^**+**^Thy1.1^**+**^ Ly5.1^**+**^ cells or CD8^**+**^Ly5.2^**+**^.

Bioenergetic analyses {#S21}
---------------------

CD8^**+**^ T cells were re-suspended in serum-free unbuffered DMEM medium (Sigma-Aldrich) supplemented with L-glutamine (200 mM), NaCl (143 mM), D-glucose (25 mM), and sodium pyruvate (1 mM). Cells were then plated onto Seahorse cell plates (10^6^ cells per well), coated with Cell-Tak (Corning) to facilitate T cell attachment. Mitochondrial stress test was performed by measuring OCR (pmol/min) at steady state and after sequential injection of oligomycin (0.5 μM), FCCP (0.5 μM), rotenone (1 μM) and antimycin A (1 μM) (Sigma-Aldrich). In some experiments, etomoxir (43 μM) was injected prior to rotenone and antimycin A. Experiments with the Seahorse system utilized the following assay conditions: 2 min mixture; 2 min wait; and 3 min measurement.

RNA-seq {#S22}
-------

RNA concentration was determined with the Qubit RNA broad range assay in the Qubit Fluorometer (Invitrogen) and RNA integrity was determined with Eukaryote Total RNA Nano Series II Chip on a 2100 Bioanalyzer (Agilent). RNA-seq libraries were prepared from 4 μg of total RNA via the TruSeq RNA sample prep kit according to manufacturer's protocol (Illumina). In brief, oligo-dT purified mRNA was fragmented and subjected to first and second strand cDNA synthesis. cDNA fragments were blunt-ended, ligated to Illumina adaptors, and PCR amplified to enrich for the fragments ligated to adaptors. The resulting cDNA libraries were verified and quantified on Agilent Bioanalyzer and sequencing (2×75 bp paired-end) was conducted on GAIIx Genome Analyzer (Illumina). RNA-seq analyses were performed using 3 biological replicates. RNA sequencing was performed and analyzed as described previously. Briefly, total RNA was prepared from cells using the RNeasy Plus Mini Kit (Qiagen). 200 ng total RNA was subsequently used to prepare RNA-seq library by using TruSeq RNA sample prep kit (FC-122--1001, Illumina) according to the manufacturer's instructions. Sequenced reads were aligned to the mouse genome (NCBI37/mm9) with TopHat 2.0.11^[@R53]^, and uniquely mapped reads were used to calculate gene expression. The mouse genome reference sequences (mm9) and the genome annotation were downloaded from the UCSC genome browser for RNA-seq analysis. Raw counts that fell on transcripts of each gene were calculated, and differentially expressed genes were identified with the statistical R package DESeq2^[@R54]^. Differentially expressed genes were required to meet to the criteria: fold change \> 1.5 or \< 1.5, and false discovery rate \< 0.05. Expression heatmaps were generated with the Bioconductor Package ComplexHeatmap^[@R55]^.

Gene-Set enrichment and pathway analyses {#S23}
----------------------------------------

Mouse gene symbols were first mapped to the orthologous human genes using the homology information available from the MGI website (<ftp://ftp.informatics.jax.org/pub/reports/HMD_HGNC_Accession.rpt>) and were ranked by the fold changes of the gene expression as profiled by RNA-seq. Then, gene set enrichment was analyzed using GSEA software ([http://software.broadinstitute.org/gsea/downloads.jsp)^[@R56]^](http://software.broadinstitute.org/gsea/downloads.jsp)56). Pathway Analysis was performed on the identified differentially expressed genes list using the Core Analysis function included in Ingenuity Pathway Analysis (IPA, Qiagen).

CFSE and MitoTracker Green labeling {#S24}
-----------------------------------

CD8^+^ T cells were incubated with 1 μL of CFSE (Thermo Fischer \# C34554) in 1ml protein-free PBS for 20 minutes at 37°C with agitation followed. For MitoTracker Green staining, CD8^+^ T cells were incubated with 250nM MitoTracker Green FM (Molecular Probes) for 30 minutes at 37°C.

Cytolytic assay {#S25}
---------------

Target cell lysis was evaluated with the xCELLigence Real-Time Cell Analyzer (ACEA Biosciences). Electrical impedance due to B16-hgp100 was measured every 15 minutes until the end of the experiment. The data were processed using the xCELLigence RTCA software package (version 2.0), and the results are reported as a cell index value (CI), where CI = (impedance at time point n -- impedance in the absence of cells)/nominal impedance value. CI was normalized to 1 at the time when T cells were added. Percentage of lysis was calculated for values obtained after 18h of co-culture and different T cell:B16-hgp100 ratios.

Statistical analyses {#S26}
--------------------

Using Graphpad Prism 7, a two-tailed Student's t-test was used for comparison of data such as gene expression levels, cell proliferation and functionality (numbers and percentage), and tumor growth slopes. A Log-rank (Mantel-Cox) Test was used for comparison of survival curves.

Reporting summary. {#S27}
------------------

Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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![c-Myb promotes the formation stem cell-like T~CM~ cells by restraining terminal differentiation.\
(**a**) Immunoblot showing c-Myb in naïve CD8^+^ T cells from pmel-1 *Myb*^fl/fl^ *Cre- ER*^*T2*^ mice 5d after i.p. treatment with tamoxifen or vehicle. GAPDH served as control. (**b**) Flow cytometry of pmel-1 *Myb*^fl/fl^ and *Myb*^Δ/Δ^ CD8^+^ T cells after naïve T cell enrichment. (**c**) Experimental design testing c-Myb impact on pmel-1 CD8^+^ T cell primary and secondary immune responses. gp100-VV, vaccinia virus encoding human gp100; gp100-adV, adenovirus type 2 encoding human gp-100. (**d**,**e**) Flow cytometry of splenic CD8^+^ T cells (**d**) and numbers of pmel-1 T cells (**e**) after transfer of 10^5^ pmel-1 Thy1.1 *Myb*^fl*/*fl^ or pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ CD8^+^ T cells into wild-type mice infected with gp100-VV, assessed 0--30 d after infection (*n* = 3 mice per group per time point). (**f**) Flow cytometry of pmel-1 T cells 5d after transfer as in **d**,**e**. (**g**) Percentages (left) and numbers (right) of CD62L^*−*^ KLRG1^+^ and CD62L^+^ KLRG1^*−*^ pmel-1 T cells 5d after transfer as in **d**,**e**. (**h**) Flow cytometry (left) and geometric Mean Fluorescence Intensity (right) of pmel-1 T cells 5d after transfer as described in **d**. (**i**) Cell index (top) and percentage of lysis (bottom) of B16-hgp100 melanoma after co-culture with pmel-1 *Myb*^+*/*+^ or pmel-1 *Myb*^Δ*/*Δ^ CD8^+^ T cells (*n* = 6 technical replicates) (**j**,**k**) Intracellular cytokine staining (**j**) and combinatorial cytokine production (**k**) by pmel-1 T cells 5d after transfer as in **d**,**e**. (**l**) Oxygen consumption rate (OCR) of pmel-1 *Myb*^+*/*+^ and pmel-1 *Myb*^Δ*/*Δ^ CD8^+^ T cells activated *in vitro* with anti-CD3 and anti-CD28 antibodies in the presence of IL-2. Data are shown under basal condition and in response to the indicated molecules (*n* = 5 technical replicates). FCCP, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; Ant, Antimycin; Rot, Rotenone. (**m**, **n**) Basal OCR (**m**) and SRC (**n**) of pmel-1 T cells generated as in **l** (*n* = 15 technical replicates; 5 replicates x 3 time points). SRC, spare respiratory capacity. (**o**) Flow cytometry of pmel-1 T cells in the lymph nodes 30d after transfer as in **d**,**e**. (**p**) Percentage of KLRG1^*−*^CD62L^+^ pmel1 T cells in the lymph nodes 30d after transfer as in **d**,**e**. (**q**,**r**) Flow cytometry of splenocytes (**q**) and numbers of splenic pmel-1 T cells (**r**) 5d after the transfer of 5 × 10^4^ pmel-1 Ly5.2 *Myb*^fl/fl^ and pmel-1 Ly5.2 *Myb*^Δ/Δ^ primary memory CD8^+^ T cells followed by secondary infection with gp100-adV (*n* = 3). Data are representative of at least two independent experiments. Data are shown after gating on live CD8^+^ (**b, d**), CD8^+^ Thy1.1^+^ cells (**f**, **h**, **j**, **o**) and CD8^+^ Ly5.2^+^ (**q**). Data in **e**, **g**, **h**, **j**, **i**, **l**, **m**, **n**, **p** and **r** are shown as mean ± s.e.m.; shapes represent individual mouse (**g**, **h**, **p** and **r**) or technical replicates (**i**, **m**, **n**). \*= *P* \< 0.05, \*\*= *P* \< 0.01, \*\*\*= *P* \< 0.001 and \*\*\*\*= *P* \< 0.0001, ns=non-significant (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0001){#F1}

![c-Myb is indispensable for CD8^+^ T cell stemness.\
(**a**) Experimental design assessing c-Myb function in long-term memory. (**b**) Flow cytometry of splenic CD8^+^ T cells after transfer of 3×10^5^ pmel-1 Thy1.1 *Myb*^fl*/*fl^ or pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ CD8^+^ T cells into wild-type mice infected with gp100-VV, assessed 90d after infection (*n* = 3 mice per group). (**c**) Numbers of total (left) and CD62L^+^ KLRG1^*−*^ (right) pmel-1 T cells after transfer as in **b**. (**d**) Experimental design testing c-Myb impact on secondary memory. Middle, flow cytometry exemplifying Thy1.1^+^ T cell frequencies 45d after transfer as in **b**. (**e**, **f**) Flow cytometry of splenocytes (**e**) and numbers of splenic pmel-1 Thy1.1 CD8^+^ T cells (**f**) after transfer of 5 ×10^4^ primary memory pmel-1 Thy1.1 *Myb*^fl*/*fl^ or pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ CD8^+^ T cells, assessed 30d after gp100-adV infection (*n* = 3 mice per group). (**g**) Flow cytometry of splenic pmel-1 T cells 30d after transfer as in **e**,**f**. (**h**) Numbers of splenic CD62L^+^ KLRG1^*−*^ pmel1 T cells obtained as in **g**. (**i**) Experimental design evaluating self-renewal of stem cell--like T~CM~ cells. Middle, flow cytometry exemplifying the sorting strategy for isolation of CD62L^+^ pmel-1 memory T cells from spleens and lymph nodes 45d after transfer of 10^6^ pmel-1 Thy1.1 *Myb*^fl/fl^ or pmel-1 Thy1.1 *Myb*^Δ/Δ^ CD8^+^ T cells into wild-type mice infected with gp100-VV. (**j**) Flow cytometry of pmel-1 Thy1.1 CD8^+^ T cells 28d after transfer of 10^5^ CFSE-labeled CD62L^+^ pmel-1 Thy1.1 *Myb*^fl*/*fl^ or pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ CD8^+^ T cells into sub-lethally irradiated mice (*n* =2 mice per group, data shown after concatenating). Data are shown after gating on live (**e**) live, CD8^+^ (**b, d**) and live, CD8^+^ Thy1.1^+^ cells (**g**, **j**). Data in **c**, **f**, **h** are shown as mean ± s.e.m.; shapes represent individual mice (**c**, **f**, **h**). \*= *P* \< 0.05, \*\*= *P* \< 0.01 and \*\*\*= *P* \< 0.001 (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0002){#F2}

![c-Myb enhances CD8^+^ T cell stemness by regulating *Tcf7*, *Bcl2*, and *Zeb2* expression\
(**a**) Volcano plot showing changes in gene expression between pmel-1 *Myb*^+*/*+^ and pmel-1 *Myb*^Δ*/*Δ^ T cells. Gene expression was evaluated by RNA-seq of pmel-1 KLRG1^*−*^CD62L^*−*^ T cells isolated 5 days after transfer of 3 X 10^5^ pmel-1 Thy1.1 *Myb*^+*/*+^ and pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ CD8^+^ T cells into wild-type mice infected with gp100-VV (*n* = 3, each from 2 pooled mice per group). Triangles and squares represent genes enriched in central memory (T~CM~) and terminal effector (T~TE~ ) T cells^[@R57]^, respectively. Red and blue represent genes activated and repressed by c-Myb in promyelocytes, respectively ^[@R28]^. (**b**) Gene Set Enrichment Assay showing positive enrichment of genes upregulated in cells lacking Wnt signaling^[@R33]^ (left) and in *Zeb2*-sufficient cells^[@R32]^ (panel) in pmel-1 *Myb*^Δ*/*Δ^ T cells obtained as in **a**. (**c**--**e**). Quantitative RT-PCR of *Bcl2* (**c**), *Tcf7* (**d**) and *Zeb2* (**e**) mRNA in comparison to *Myb* in naïve, CD62L^+^ and CD62L^−^ pmel-1 T cells sorted 5d after transfer of 10^5^ pmel-1 *Myb*^+*/*+^ CD8^+^ T cells as in **a**. Results are relative to *Rpl13* (*Bcl2*, *Tcf7* and *Zeb2*) or *Actb* (*Myb*) (*n* = 3 technical replicates). (**f**--**h**) Quantitative RT-PCR of *Bcl2* (**f**), *Tcf7* (**g**) and *Zeb2* (**h**) mRNA in pmel-1 CD62L^+^ T cells sorted 5d after transfer of 10^5^ pmel-1 Thy1.1 *Myb*^+*/*+^, pmel-1 Thy1.1 *Myb*^Δ*/*Δ^, pmel-1 Thy1.2^+^ engineered with *Myb*-Thy1.1 or Thy1.1 as in **a**. Results are relative to *Rpl13* (*n* = 3 technical replicates). (**i**,**j**) Flow cytometry of pmel-1 T cells 5d after transfer of 10^5^ pmel-1 Thy1.1 *Myb*^+*/*+^, pmel-1 Thy1.1 *Myb*^Δ*/*Δ^ as in **a**. Numbers indicate geometric Mean Fluorescence Intensity ± s.e.m. (*n* = 3 mice per group) (**k**) ChIP-qPCR of *in vitro* activated pmel-1 *Myb*^+*/*+^ or pmel-1 *Myb*^Δ*/*Δ^ CD8^+^ T cells. Chromatin was precipitated with anti-c-Myb or anti-IgG antibodies and amplified with primers specific to *Tcf7* enhancer and *Zeb2* promoter regions (*n* = 3 technical replicates). **l**, **n** Flow cytometry of splenic pmel-1 T cells (**l**) and CD8+ T cells (**n**) after transfer of 10^5^ pmel-1 *Myb*^fl*/*fl^, pmel-1 *Myb*^Δ*/*Δ^ or pmel-1 *Myb*^Δ*/*Δ^ *Zeb2*^+*/*Δ^ CD8^+^ T cells transduced with pMI-GFP or pMI-GFP-*Tcf7* 10 d after transfer into wild-type mice infected with gp100-VV. **m**, **o** Percentage of KLRG1^+^CD62L^*−*^GFP^+^CD8^+^ T cells (**m**) and CD8^+^ GFP^+^ T cells (**o**) 10 d after transfer as in **l**. Data are representative of two independent experiments. Data are shown after gating on live CD8^+^ Thy1.1^+^ cells (**i**, **j**), live CD8^+^ GFP^+^ cells (**l**) or live CD8^+^ cells (**n**). Data in **c**--**h**, **k**,**m**,**o** are mean ± s.e.m.; each symbol represents an individual mouse (**m**, **o**) or technical replicate (**c**--**h**, **k**). **m**, merged data from two independent experiments. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \<  0.001 and \*\*\*\**P* \< 0.0001 (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0003){#F3}

![Distinct functions of c-Myb domains in the regulation of CD8^+^ T cell differentiation and survival.\
(**a**) Truncated and mutated versions of c-Myb employed for complementation studies. (**b**) Flow cytometry of splenic pmel-1 Thy1.1 CD8^+^ T cells 5d after transfer of 10^5^ pmel-1 *Myb*^Δ*/*Δ^ CD8^+^ T cells, transduced with MSGV-Thy1.1 encoding wild-type or mutated c-Myb forms, into Ly5.1 mice infected with gp100-VV. pmel-1 *Myb*^+*/*+^ and pmel-1 *Myb*^Δ*/*Δ^ CD8^+^ T cells transduced with Thy1.1 served as control (*n* = 3 mice per group). (**c**) Percentage of KLRG1^+^ CD62L^*−*^ pmel-1 T cells 5d after transfer as in **b**. Quantitative RT-PCR of *Tcf7* (**d**) and *Zeb2* (**e**) mRNA in pmel-1 T cells sorted 5d after transfer as in **b**. Results are relative to *Rpl13* (*n* = 3 technical replicates). (**f**) Flow cytometry of CD8^+^ T cells 5d after transfer as described in **b**. (**g**) Percentage of splenic CD8^+^ Thy1.1^+^ T cells 5d after transfer as described in **b**. Data are representative of at least two independent experiments. Data are shown after gating on live CD8^+^ Thy1.1^+^ cells (**b**), and live CD8^+^ cells (**f**). Data in **c**--**e**, and **g** are shown as the mean ± s.e.m.; shapes represent individual mice (**c** and **g**) or technical replicates (**d**,**e**). \*\*= *P* \< 0.01, \*\*\*= *P* \< 0.001 and \*\*\*\*= *P* \< 0.0001; ns, non-significant (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0004){#F4}

![*Myb* overexpression enhances CD8^+^ T cell memory and polyfunctionality.\
(**a**) Experimental design evaluating the impact of *Myb* overexpression in CD8^+^ T cell memory formation. Left, immunoblot of c-Myb in Thy1.1 and *Myb*-Thy1.1 overexpressing cells. Right, flow cytometry of the 1:1 mixture of Thy1.1 and *Myb*-Thy1.1 CD8^+^ T cells before transfer into mice. gp100-VV, vaccinia virus encoding human gp100 (**b**,**c**) Flow cytometry of splenic CD8^+^ T cells (**b**) and numbers of pmel-1 T cells (**c**) after co-transfer of 5 × 10^4^ pmel-1-Thy1.1 and 5 × 10^4^ pmel-1 Ly5.1 *Myb*-Thy1.1 CD8^+^ T cells into wild-type mice infected with gp100-VV. Assessed 0--32d after transfer (*n* = 3 mice per group per time point). (**d**) Flow cytometry analysis of splenic pmel-1 T cells after transfer as in **b**,**c**. (**e**) Percentage of KLRG1^*−*^CD62L^+^ (upper panel) and KLRG1^+^ CD62L^*−*^ (lower panel) splenic pmel-1 T cells after transfer as in **b**,**c**. (**f**) Percentage of cytokine producing pmel-1 T cells after transfer as described in **b**,**c**. (**g**, **h**) Intracellular cytokine staining (**g**) and combinatorial cytokine production (**h**) by splenic pmel-1 T cells 5d after transfer as in **b**,**c**. Data are representative of two independent experiments. Data are shown after gating on live CD8^+^ cells (**b**), and live CD8^+^ Thy1.1^+^ (**d**, **g**). Data in **c**, **e**, and **f** are shown as the mean ± s.e.m.; shapes represent individual mice. \*= *P* \< 0.05, \*\*= *P* \< 0.01, \*\*\*= *P* \< 0.001 and \*\*\*\*= *P* \< 0.0001 (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0005){#F5}

![*Myb* overexpression enhances CD8^+^ T recall responses.\
(**a**) Experimental design testing the impact of *Myb* overexpression on CD8^+^ T cell secondary responses. gp100-VV, vaccinia virus encoding human gp100; gp100-adV, adenovirus type 2 encoding gp-100. (**b**, **c**) Flow cytometry of splenic CD8^+^ T cells (**b**) and numbers of pmel-1 CD8^+^ T cells (**c**) after co-transfer of 5 × 10^4^ pmel-1-Thy1.1 and 5 × 10^4^ pmel-1 Ly5.1 *Myb*-Thy1.1 CD8^+^ T cells into wild-type mice infected with gp100-VV, assessed 5d after secondary infection with gp100-adV (*n* = 3 mice per group). (**d**--**f**) Flow cytometry of pmel-1 T cells in the spleen (**d**), lungs (**e**) and lymph nodes (**f**) 5d after secondary infection as in **b**,**c**. (**g**--**i**) Percentage of KLRG1^*−*^CD62L^+^ and KLRG1^+^ CD62L^*−*^ pmel-1 T cells in the spleen (**g**), lungs (**h**) and lymph nodes (**i**) 5d after secondary infection as in **b**,**c**. (**j**) Percentage of cytokine^+^ splenic pmel-1 T cells 5d after secondary infection as in **b**,**c**. (**k**, **l**) Intracellular cytokine staining (**k**) and combinatorial cytokine production (**l**) by splenic pmel-1 T cells 5d after secondary infection as in **b**,**c**. Data are representative of two independent experiments. Data are shown after gating on live CD8^+^ cells (**b**), and live CD8^+^ Thy1.1^+^ (**d**--**f**, **k**). Data in **c**, and **g**--**j**, are shown as the mean ± s.e.m.; shapes represent individual mice. \*= *P* \< 0.05, \*\*= *P* \< 0.01; ns, non-significant (unpaired two-tailed Student's *t*-test).](nihms-1517146-f0006){#F6}

![Enforced expression of *Myb* enhances CD8^+^ T cell antitumor immunity.\
(**a**) Fold expansion of pmel-1 CD8^+^ T cell*s* transduced with Thy1.1 or *Myb*-Thy1.1 cells after priming with anti-CD3 anti-CD28 antibodies and re-stimulation with the same antibodies 5d later. Cells were grown in the presence of IL-2 throughout the culture (*n* = 3 independent experiments). (**b, c**) Flow cytometry of pmel-1 T cell*s* transduced with Thy1.1 or *Myb*-Thy1.1 generated as described in **a**. (**d**) geometric Mean Fluorescence Intensity (gMFI) of mitotracker staining in pmel-1 T cell*s* generated as in **a**. (*n* = 3 technical replicates) (**e**) Oxygen consumption rate (OCR) of pmel-1 T cell*s* generated as in **a**., assessed on 10d. Data are shown under basal culture conditions and in response to the indicated molecules (*n* = 12 technical replicates). FCCP, Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; Ant, Antimycin; Eto, Etomoxir; Rot, Rotenone. (**e**,**f**) Spare respiratory capacity (SRC) (**g**) and reduction of OCR after Eto administration in pmel-1 T cell*s* generated as in **a**., assessed on 10d (*n* = 36 technical replicates; 12 replicates x 3 time points) (**i**) Tumor curve (left panel) and survival (right panel) of wild-type mice bearing subcutaneous hgp100^+^ B16 melanoma cells after transfer of 5 X 10^6^ pmel-1 T cells generated as in **a** in conjunction with gp100-VV and IL-2 (*n* = 5 mice per group). Solid and dashed red curve denotes tumor challenged mice that received no T cell transfer. On 206d post-T cell transfer, mice were re-challenged with 2.5 × 10^5^ hgp100^+^ B16 melanoma. Data are representative of two independent experiments. Tumor re-challenge after 200d was performed in an individual experiment. Data are shown after gating on live CD8^+^ cells (**b**, **c**) Data in **a**, **d**--**g** are shown as the mean ± s.e.m.; each tumor curve represents an individual mouse \*= *P* \< 0.05, \*\*\*= *P* \< 0.001 (**a**, unpaired two-tailed Student's *t*-test; **h**, a Log-rank (Mantel-Cox) Test).](nihms-1517146-f0007){#F7}
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